A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Sarit Assouline; Laura C. Michaelis; Megan Othus; Annette E. Hay; Roland B. Walter; Meagan A. Jacoby; Mark A. Schroeder; Geoffrey L. Uy; Lisa Y. Law; Faisal Cheema; Kendra L. Sweet; Adam S. Asch; Jijun Liu; Anna B. Moseley; Tracy Maher; Laura L. Kingsbury; Min Fang; Jerald Radich; Richard F. Little; Harry P. Erba

doi:10.1080/10428194.2022.2148212

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Sarit Assouline, Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby, Mark A. Schroeder, Geoffrey L. Uy, Lisa Y. Law, Faisal Cheema, Kendra L. Sweet, Adam S. Asch, Jijun Liu, Anna B. Moseley, Tracy Maher, Laura L. Kingsbury, Min Fang, Jerald Radich, Richard F. Little, Harry P. Erba

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English
Pages (from-to)	473-477
Number of pages	5
Journal	Leukemia and Lymphoma
Volume	64
Issue number	2
DOIs	https://doi.org/10.1080/10428194.2022.2148212
State	Published - 2023

Access to Document

10.1080/10428194.2022.2148212

Cite this

Assouline, S., Michaelis, L. C., Othus, M., Hay, A. E., Walter, R. B., Jacoby, M. A., Schroeder, M. A., Uy, G. L., Law, L. Y., Cheema, F., Sweet, K. L., Asch, A. S., Liu, J., Moseley, A. B., Maher, T., Kingsbury, L. L., Fang, M., Radich, J., Little, R. F., & Erba, H. P. (2023). A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leukemia and Lymphoma, 64(2), 473-477. https://doi.org/10.1080/10428194.2022.2148212

Assouline, Sarit ; Michaelis, Laura C. ; Othus, Megan et al. / A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older : a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. In: Leukemia and Lymphoma. 2023 ; Vol. 64, No. 2. pp. 473-477.

@article{3b4c842c95344b9f8809ea6999b540ed,

title = "A randomized phase II/III study of {\textquoteleft}novel therapeutics{\textquoteright} versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612",

author = "Sarit Assouline and Michaelis, {Laura C.} and Megan Othus and Hay, {Annette E.} and Walter, {Roland B.} and Jacoby, {Meagan A.} and Schroeder, {Mark A.} and Uy, {Geoffrey L.} and Law, {Lisa Y.} and Faisal Cheema and Sweet, {Kendra L.} and Asch, {Adam S.} and Jijun Liu and Moseley, {Anna B.} and Tracy Maher and Kingsbury, {Laura L.} and Min Fang and Jerald Radich and Little, {Richard F.} and Erba, {Harry P.}",

note = "Funding Information: This work supported by National Institutes of Health/National Cancer Institute Grant Awards U10CA180888, U10CA180819, U10CA180821, U10CA180863, UG1CA233198, UG1CA233328, UG1CA189821, UG1CA233339, P30CA076292, UG1CA233193, and UG1CA189830. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.",

year = "2023",

doi = "10.1080/10428194.2022.2148212",

language = "English",

volume = "64",

pages = "473--477",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

number = "2",

}

Assouline, S, Michaelis, LC, Othus, M, Hay, AE, Walter, RB, Jacoby, MA , Schroeder, MA , Uy, GL, Law, LY, Cheema, F, Sweet, KL, Asch, AS, Liu, J, Moseley, AB, Maher, T, Kingsbury, LL, Fang, M, Radich, J, Little, RF & Erba, HP 2023, 'A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612', Leukemia and Lymphoma, vol. 64, no. 2, pp. 473-477. https://doi.org/10.1080/10428194.2022.2148212

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. / Assouline, Sarit; Michaelis, Laura C.; Othus, Megan et al.
In: Leukemia and Lymphoma, Vol. 64, No. 2, 2023, p. 473-477.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older

T2 - a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

AU - Assouline, Sarit

AU - Michaelis, Laura C.

AU - Othus, Megan

AU - Hay, Annette E.

AU - Walter, Roland B.

AU - Jacoby, Meagan A.

AU - Schroeder, Mark A.

AU - Uy, Geoffrey L.

AU - Law, Lisa Y.

AU - Cheema, Faisal

AU - Sweet, Kendra L.

AU - Asch, Adam S.

AU - Liu, Jijun

AU - Moseley, Anna B.

AU - Maher, Tracy

AU - Kingsbury, Laura L.

AU - Fang, Min

AU - Radich, Jerald

AU - Little, Richard F.

AU - Erba, Harry P.

N1 - Funding Information: This work supported by National Institutes of Health/National Cancer Institute Grant Awards U10CA180888, U10CA180819, U10CA180821, U10CA180863, UG1CA233198, UG1CA233328, UG1CA189821, UG1CA233339, P30CA076292, UG1CA233193, and UG1CA189830. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

PY - 2023

Y1 - 2023

UR - http://www.scopus.com/inward/record.url?scp=85144130323&partnerID=8YFLogxK

U2 - 10.1080/10428194.2022.2148212

DO - 10.1080/10428194.2022.2148212

M3 - Letter

C2 - 36517990

AN - SCOPUS:85144130323

SN - 1042-8194

VL - 64

SP - 473

EP - 477

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 2

ER -

Assouline S, Michaelis LC, Othus M, Hay AE, Walter RB, Jacoby MA et al. A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leukemia and Lymphoma. 2023;64(2):473-477. doi: 10.1080/10428194.2022.2148212

Access to Document

Other files and links

Cite this